ArticleInternational journal of clinical pharmacy2024

Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States.

Hongbin Yi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.